Evidence map›Paper›PMID 33356372›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2021

New Cellular Source of TF (Tissue Factor)-Positive Extracellular Vesicles in the Circulation.

Silvio Antoniak, Nigel Mackman

Abstract readEditorialComment
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Silvio AntoniakDepartment of Medicine, UNC Blood Research Center (S.A., N.M.), University of North Carolina at Chapel Hill.
Nigel MackmanDepartment of Medicine, UNC Blood Research Center (S.A., N.M.), University of North Carolina at Chapel Hill.

Funding

Tissue factor-dependent coagulation in thrombosis and immune responsesR35HL155657 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nigel Mackman · 2021 to 2026
$5.5M
Role of the Thrombin PAR-1 Pathway in Viral InfectionR01HL119523 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MACKMAN, NIGEL · 2013 to 2020
$3.0M
PAR1 as a Therapeutic Target in Doxorubicin-induced CardiotoxicityR01HL148432 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANTONIAK, SILVIO · 2020 to 2023
$2.3M
Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responsesR01HL142799 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANTONIAK, SILVIO · 2018 to 2022
$1.9M
NHLBI NIH HHS R01 HL119523NHLBI NIH HHS R01 HL142799NHLBI NIH HHS R01 HL148432NHLBI NIH HHS R35 HL155657
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell-Derived MicroparticlesExtracellular VesiclesAldehydesOxidative StressThromboplastin4-hydroxy-2-nonenalAldehydesThromboplastincytokineEditorialsfibroblastmonocyteoxidative stresstissue factor

Identifiers

PMID33356372
PMCPMC7773051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.